Suppr超能文献

验证瑞典患者登记处中心肌炎诊断的准确性,以分析 COVID-19 疫苗的潜在不良反应。

Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines.

机构信息

Department of Efficacy and Safety 1, Division of Licensing, Medical Products Agency, Uppsala, Sweden.

Department of Surgical Sciences, Uppsala University, Sweden.

出版信息

Ups J Med Sci. 2023 May 11;128. doi: 10.48101/ujms.v128.9290. eCollection 2023.

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain.

METHODS

Patient records for subjects < 40 years of age and a diagnosis of myocarditis in the Swedish National Patient Register were manually reviewed. Brighton Collaboration diagnosis criteria for myocarditis were applied based on patient history, clinical examination, laboratory data, electrocardiograms, echocardiography, magnetic resonance imaging and myocardial biopsy. Poisson regression was used to estimate incidence rate ratios, comparing the register-based outcome variable to validated outcomes. Interrater reliability was assessed by a blinded re-evaluation.

RESULTS

Overall, 95.6% (327/342) of cases registered as myocarditis were confirmed (definite, probable or possible myocarditis according to Brighton Collaboration diagnosis criteria, positive predictive value 0.96 [95% CI 0.93-0.98]). Of the 4.4% (15/342) cases reclassified as no myocarditis or as insufficient information, two cases had been exposed to the COVID-19 vaccine no more than 28 days before the myocarditis diagnosis, two cases were exposed >28 days before admission and 11 cases were unexposed to the vaccine. The reclassification had only minor impact on incidence rate ratios for myocarditis following COVID-19 vaccination. In total, 51 cases were sampled for a blinded re-evaluation. Of the 30 randomly sampled cases initially classified as either definite or probably myocarditis, none were re-classified after re-evaluation. Of the in all 15 cases initially classified as no myocarditis or insufficient information, 7 were after re-evaluation re-classified as probable or possible myocarditis. This re-classification was mostly due to substantial variability in electrocardiogram interpretation.

CONCLUSION

This validation of register-based diagnoses of myocarditis by manual patient record review confirmed the register diagnosis in 96% of cases and had high interrater reliability. Reclassification had only a minor impact on the incidence rate ratios for myocarditis following COVID-19 vaccination.

摘要

背景

使用医院出院诊断作为结局,COVID-19 mRNA 疫苗与心肌炎风险增加相关。这些基于登记的诊断的有效性尚不确定。

方法

对瑞典国家患者登记处年龄<40 岁且诊断为心肌炎的患者记录进行了手动审查。根据患者病史、临床检查、实验室数据、心电图、超声心动图、磁共振成像和心肌活检,应用布莱顿合作组织心肌炎诊断标准。使用泊松回归比较登记的结局变量与验证的结局,估计发病率比值比。通过盲法重新评估评估了组内可靠性。

结果

总体而言,342 例登记为心肌炎的病例中,95.6%(327/342)得到了证实(根据布莱顿合作组织诊断标准为明确、可能或可能的心肌炎,阳性预测值为 0.96[95%CI 0.93-0.98])。在重新分类为无心肌炎或信息不足的 4.4%(15/342)病例中,有 2 例在心肌炎诊断前 28 天内接触过 COVID-19 疫苗,2 例在入院前 28 天以上接触过疫苗,11 例未接触过疫苗。重新分类对 COVID-19 疫苗接种后心肌炎的发病率比值比影响较小。总共对 51 例进行了盲法重新评估。在最初分类为明确或可能心肌炎的 30 例随机样本中,无一例在重新评估后被重新分类。在所有最初分类为无心肌炎或信息不足的 15 例中,有 7 例在重新评估后被重新分类为可能或可能的心肌炎。这种重新分类主要是由于心电图解释的差异较大。

结论

通过手动患者记录审查对基于登记的心肌炎诊断进行验证,96%的病例证实了登记诊断,组内可靠性较高。重新分类对 COVID-19 疫苗接种后心肌炎的发病率比值比影响较小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6a2/10202079/f6eb7d7804ed/UJMS-128-9290-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验